FLT3xCD3 BsAb / Hemogenyx - LARVOL DELTA

Hemogenyx Pharmaceuticals PLC Announces CDX Development Update (Yahoo Finance) - "Hemogenyx Pharmaceuticals plc...is pleased to announce that it has developed a new and improved version of its bi-specific antibody ('CDX') for the treatment of relapsed/refractory acute myeloid leukaemia ('AML'), a subset of acute lymphoblastic leukaemia ('ALL'), and potentially for conditioning in bone marrow transplantations. The Company's scientists utilised Lonza's bYlok bispecific pairing technology to develop a new and improved version of CDX, which has demonstrated significantly enhanced efficacy in in vitro testing. Additional in vivo studies are currently underway."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia

Hemogenyx Pharmaceuticals PLC Announces Operations Update (ACCESSWIRE) - "Scientists at Hemogenyx Pharmaceuticals are developing and testing multiple CBR constructs to identify the best candidates for targeting rare cancers such as epithelial ovarian carcinoma. Selected candidates will undergo rigorous testing to advance them to investigational new drug (IND) enabling studies....The Company is advancing IND-enabling studies for CDX, a bispecific antibody designed for treating relapsed and/or refractory AML, a subset of ALL, and for conditioning in bone marrow transplants."

Preclinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Gynecologic Cancers • Hematological Malignancies • Leukemia • Oncology • Ovarian Cancer • Solid Tumor

Hemogenyx Pharmaceuticals PLC Announces Final Results for the Year Ended 31 December 2022 (Issuer Direct) - "Key Highlights: Nearing completion of the IND application to the FDA to enter phase I clinical trials for HEMO-CAR-T for the treatment of R/R AML....Initiated IND-enabling activities for CDX bi-specific antibody for treatment of R/R AML."

IND • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology